Estudiar las necesidades de los pacientes oncológicos sobre la información referida a su enfermedad y los cuidados al final de la vida. Métodos: 820 pacientes participaron de una encuesta sobre diagnóstico, pronóstico, eficacia y toxicidad de los tratamientos, así como también sobre cuidados paliativos, investigación clínica, apoyo psicológico, cuidados espirituales y deseos del final de la vida. Resultados: 695 pacientes conocen su diagnóstico, especialmente quienes tenían un mayor nivel educativo y un rango etario de 50-70 años. Seiscientos setenta y cuatro pacientes deseaban conocer su pronóstico, estando más predispuestos a conocerlo quienes tenían educación secundaria y superior. La mayoría (562 pacientes) deseaba conocer todo con respecto a la utilidad de los tratamientos, al igual que con respecto a la toxicidad (443) y valoraría contar con información sobre cuidados paliativos e investigación. Además consideraba la internación hospitalaria como el mejor lugar para morir (331). Las mujeres se mostraron más propensas a recibir ayuda psicológica y espiritual. Las condiciones más valoradas en el médico fueron: conocimiento (52,7%), Honestidad (45,5%) y Humanidad (44,3%).

No abstract

No abstract

e22023 Background: Use of ICI changed the treatment of Advanced Cutaneous Melanoma Patients (ACMP). This paper analyzes the evolution of ACMP who develop vitiligo during ICI treatment at Instituto Oncológico Henry Moore (IOHM). Methods: We selected all ACMP that received ICI between August 2015 and December 2019. We collected clinical data and compared Group A (ACMP with vitiligo) with Group B (ACMP without vitiligo) on: response rate (RR), time from ICI treatment initiation to progression (TTP) and overall survival (OS), defined as time from ICI treatment initiation to death. Outcomes were assessed using table tests and Kaplan-Meier curves with log-rank test. Results: Out of 32 ACMP treated with ICI, 12 Pt (37%) were in Group A and 20 Pt (63%) were in Group B. Table shows group characteristics and outcomes. Conclusions: 1) During treatment with ICI, 12 out of 32 (37%) advanced cutaneous melanoma patients were afflicted with vitiligo. 2) Two out of three patients who responded to ICI treatment developed vitiligo and obtained better TTP and OS than those without vitiligo. 3) According to these results, vitiligo is the consequence of the immune system reactivation responsible for considerable clinical benefits. Further studies should analyze if it is feasible to reduce ICI doses in patients who develop this adverse effect. 4) In this small and retrospective series, Nivolumab was more frequently correlated with vitiligo and clinical benefits, but we need prospective studies to decide which ICI treatment is the most effective. [Table: see text]

16037 Background: Evidence-based Oncology (EBO) is founded in clinical trials, medical expertise and patient’s quality of life. Pts with MPC are excluded from clinical trials and there is a lack of clinical expertise as regards to these cases. With the aim to analyze the clinical reasoning for treatment recommendation on those pts, we interviewed oncologists in charge (doc’s) at Instituto Oncológico Henry Moore (IOHM) and Universidad del Salvador (USAL). Methods: The medical records of 8,500 pts from IOHM’s database over last eight years (1997–2005) were reviewed in order to measure the incidence and characteristics of MPC pts. A total of 35 oncologists in charge were identified and participated on a survey which had ten points. The 10 items should be ranked in order of importance: 1 = the most important one and 10 = the least one. Results: One hundred and seventy eight MPC pts (2.09%) were detected, and the oncologist in charge was asked to complete the survey. All doc’s completed the survey. The following table shows the rank and the scoring for each item. (See table below) Conclusions: Four domains ( I to IV) in medical decision making for the treatment of MPC pts were identified: I = PS; II = Characteristics of the tumor; III = Morbidity from therapy and IV = Pt preferences. The pt and family preferences were ranked in the last place and it could reflect a paternalistic approach. To our understanding, this is a good model to test clinical skills and biases in medical treatment selection. [Table: see text] No significant financial relationships to disclose.